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S U M M A R Y
Background: Bolivia is among the lowest-resourced South American countries, with very few data
available on antibiotic resistance in bacterial pathogens. The phenotypic and molecular characterization
of bacterial isolates responsible for urinary tract infections (UTIs) in the Bolivian Chaco are reported here.
Methods: All clinical isolates from UTIs collected in the Hospital Basico Villa Montes between June
2010 and January 2014 were analyzed (N = 213). Characterization included susceptibility testing,
extended-spectrum beta-lactamase (ESBL) detection, identiﬁcation of relevant resistance determinants
(e.g., CTX-M-type ESBLs, 16S rRNA methyltransferases, glutathione S-transferases), and genotyping of
CTX-M producers.
Results: Very high resistance rates were observed. Overall, the lowest susceptibility was observed for
trimethoprim–sulphamethoxazole, tetracycline, nalidixic acid, amoxicillin–clavulanic acid, ciproﬂoxa-
cin, and gentamicin. Of E. coli and K. pneumoniae, 11.6% were ESBL producers. Resistance to
nitrofurantoin, amikacin, and fosfomycin remained low, and susceptibility to carbapenems was fully
preserved. CTX-M-15 was the dominant CTX-M variant. Four E. coli ST131 (two being H30-Rx) were
identiﬁed. Of note, isolates harbouring rmtB and fosA3 were detected.
Conclusions: Bolivia is not an exception to the very high resistance burden affecting many South
American countries. Optimization of alternative approaches to monitor local antibiotic resistance trends
in resource-limited settings is strongly encouraged to support the implementation of effective empiric
treatment guidelines.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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South America has long been documented as being affected by
high antibiotic resistance rates.1–5 Complex political and socio-
economic factors account for this burden, and the precise
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).deserves further attention.1–4 Bolivia is one of the lowest-
resourced countries of South America, and very few data on the
rates and molecular epidemiology of antibiotic resistance in
bacterial pathogens have been reported from this area.1–3,5
Since the late 1990s, cooperation and research activities
addressing the phenomenon of antibiotic resistance in the Bolivian
Chaco region have been performed by the present investigators, in
collaboration with the Bolivian Ministry of Health.6–13 The
healthcare system of this region, which includes many rural areas
and native villages, essentially relies upon small hospitals withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Aetiology of urinary tract infections in the Bolivian Chaco (2010–2014)
Species No. of isolates %
Escherichia coli 170 79.8
Klebsiella pneumoniae 19 8.9
Citrobacter spp 6 2.8
Enterobacter spp 5 2.3
Proteus spp 5 2.3
Morganella morganii 3 1.4
Pseudomonas aeruginosa 3 1.4
Providencia rettgeri 1 0.5
Staphylococcus saprophyticus 1 0.5
A. Bartoloni et al. / International Journal of Infectious Diseases 43 (2016) 1–62limited access to clinical microbiology facilities, which prevents
any systematic collection of antimicrobial susceptibility data from
the routine microbiological analysis of clinical specimens. By using
commensal Escherichia coli as an indicator for the dissemination of
antibiotic resistance in enterobacteria, very high resistance rates to
old antibiotics (i.e., ampicillin, trimethoprim–sulphamethoxazole,
tetracycline, chloramphenicol, and nalidixic acid) and alarmingly
increasing trends of resistance to newer drugs (i.e., expanded-
spectrum cephalosporins and ﬂuoroquinolones) have been ob-
served over the last two decades.8–13 Of note, CTX-M-type
extended-spectrum beta-lactamase (ESBL) determinants were
ﬁrst detected in this area in the early 2000s and thereafter
underwent rapid dissemination, with an evolution of the dominant
CTX-M groups mirroring that observed in other South American
countries (i.e., initial dissemination of CTX-M-2, subsequently
replaced by CTX-M-1 and CTX-M-9 groups).1–3,8,14–16
In this study, data on antimicrobial susceptibility and resistance
determinants of bacterial pathogens responsible for urinary tract
infections (UTIs) in the Bolivian Chaco region are reported. These
data were obtained by analyzing clinical isolates from UTIs
collected in the laboratory of the Hospital Basico Villa Montes (one
of the ﬁrst clinical microbiology laboratories implemented in that
region) during the ﬁrst 3 years of activity.
2. Methods
2.1. Bacterial isolates
A total of 213 non-replicate clinical isolates from UTIs were
included in the study. They represented all of the isolates from
positive urine cultures of patients with a clinical diagnosis of UTI,
submitted to the clinical microbiology laboratory of the Hospital
Basico Villa Montes (Villa Montes, Tarija Department, Bolivia)
since its activation in June 2010, up to January 2014. Clinical
isolates from both inpatients and outpatients were included. The
isolates were stored in Amies transport medium (Oxoid, Milan,
Italy) at 4 8C before being transferred to Italy.
2.2. Bacterial identiﬁcation and in vitro antibiotic susceptibility
testing
Bacterial identiﬁcation was performed by matrix-assisted laser
desorption/ionization time-of-ﬂight (MALDI-TOF) mass spectrom-
etry (Vitek MS, bioMe´rieux Inc., Marcy l’Etoile, France). Antibiotic
susceptibility was tested by disk diffusion method in accordance
with Clinical and Laboratory Standards Institute (CLSI) guide-
lines.17,18 As the CLSI does not provide interpretative criteria for
fosfomycin and Enterobacteriaceae other than E. coli, results for
the former species were interpreted using E. coli breakpoints (i.e.,
susceptible when the inhibition zone diameter is 16 mm),18 as
also reported in other studies (Endimiani et al.19 and references
therein). Screening and conﬁrmatory tests for ESBL detection were
carried out according to CLSI standards.18 The production of AmpC-
like enzymes was suspected on the basis of resistance to
cephamycins and inhibition by 3-aminophenylboronic acid.20 In
AmpC producers, the presence of ESBLs was also investigated by
modiﬁed CLSI conﬁrmatory test, as recently proposed by Poulou
et al.21Fosfomycin non-susceptible isolates were tested for the
production of glutathione S-transferases using the disk potentiation
test recently developed by Nakamura et al. (based on the inhibition
of glutathione S-transferases by sodium phosphonoformate).22
2.3. Molecular analysis techniques
The detection and characterization of blaCTX-M and blaAmpC-like
beta-lactamase genes was performed using a PCR sequencingapproach, as described previously.8,23 PCR ampliﬁcation was also
used for the detection and characterization of the fosfomycin
resistance genes fosA, fosA3, and fosC2 (encoding glutathione
S-transferases),24 the aminoglycoside resistance genes armA,
npmA, rmtA, rmtB, rmtC, rmtD, rmtE, rmtF, rmtG, and rmtH
(encoding 16S rRNA methyltransferases), and aac(60)Ib (encoding
aminoglycoside acetyltransferases).25,26 The determination of E.
coli phylogenetic groups was carried out by multiplex PCR.27
Established PCR-based methods were used to deﬁne the E. coli
clone B2-O25b-ST131 and its subclones H30 and H30-Rx.28–30
2.4. Statistical analysis
Statistical differences were determined by Chi-square test
(with Yates’ correction) and the unpaired t-test, using GraphPad
Prism for Windows, version 5.0 (GraphPad Software, San Diego, CA,
USA).
3. Results and discussion
3.1. Patient characteristics and aetiology of UTIs
A total of 213 clinical isolates considered responsible for UTIs
were collected during the study period (June 2010 to January
2014). The study started upon activation of the clinical microbiol-
ogy facility. A very low number of urine samples were processed
during the ﬁrst 2 years of activity (due to initial difﬁculties in
implementing the facility), while an increasing trend was observed
after 2012. As a consequence, the distribution of clinical isolates
over time was as follows: 2010 (7 months), n = 10; 2011, n = 12;
2012, n = 73; 2013, n = 105; 2014 (1 month), n = 13.
Of the 213 clinical isolates, 71 were from inpatients and
140 were from outpatients; the origin was unknown for two
isolates. The overall male to female patient ratio was 40:171, with
the sex of two patients unknown. Patients ranged in age from
2 months to 95 years (mean age 44 years, median age 45 years),
with the age of 16 patients unknown. Inpatient and outpatient
populations differed in age distribution (mean age 54 vs. 39 years,
median age 55 vs. 37 years; p = 0.0003), while no signiﬁcant
difference was observed in the male to female ratio (12:59 vs.
28:111; p = 0.57).
Of the 213 clinical isolates, 209 (98.1%) were Enterobacteriaceae,
three were Pseudomonas aeruginosa (1.4%), and one was a
Staphylococcus saprophyticus (0.5%) (Table 1). E. coli represented
the dominant species (79.8%), followed by Klebsiella pneumoniae
(8.9%) (Table 1), with no differences observed between inpatients
and outpatients (data not shown).
3.2. Antibiotic susceptibility
Overall, the UTI isolates collected from the Bolivian
Chaco exhibited high rates of antibiotic resistance (Table 2;
Supplementary Material Table S1).
Table 2








AMC 56.5 47.3 55.6
Cefotaxime 89.4 68.4 87.3
Ceftazidime 92.3 73.7 90.5
Meropenem 100 100 100
SXT 26.5 52.6 28.6
Nalidixic acid 51.2 63.2 52.4
Ciproﬂoxacin 61.8 68.4 62.4
Gentamicin 72.4 68.4 72.0
Amikacin 95.3 89.5 94.7
Nitrofurantoin 91.8 31.6 85.7
Fosfomycin 98.2 94.7 97.9
Tetracycline 47.1 57.9 47.6
a AMC, amoxicillin–clavulanic acid; SXT, trimethoprim–sulphamethoxazole.
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most prevalent pathogens, the most affected drugs were trimeth-
oprim–sulphamethoxazole, tetracycline, nalidixic acid, amoxicil-
lin–clavulanic acid, and ciproﬂoxacin (Table 2). Expanded-
spectrum cephalosporins remained active against the majority
of isolates (87.3% and 90.5% susceptibility to cefotaxime and
ceftazidime, respectively) (Table 2). Of the 24 isolates resistant to
cefotaxime, 22 were identiﬁed as ESBL producers (11.6% of all
E. coli and K. pneumoniae isolates). The remaining two isolates
showed a resistance phenotype suggestive of the production of
AmpC-like enzymes. Expanded-spectrum cephalosporin-resistant
isolates were signiﬁcantly more prevalent among K. pneumoniae
than E. coli isolates (31.6% vs. 10.6%; p = 0.009). Overall, the most
active drugs were meropenem, fosfomycin, amikacin, and nitro-
furantoin (the latter only for E. coli) (Table 2). K. pneumoniae
isolates exhibited very low susceptibility to nitrofurantoin, in
accordance with previous reports.31 The few non-enterobacterial
pathogens showed susceptible phenotypes typical of wild-type
strains, except for resistance to ciproﬂoxacin exhibited by one of
the three P. aeruginosa isolates (data not shown). Of note, no
signiﬁcant difference in terms of antibiotic resistance rates and
prevalence of ESBL phenotype was observed between clinical
isolates from inpatients and outpatients (data not shown), while an
increasing trend (statistically signiﬁcant for expanded-spectrum
cephalosporins, quinolones, and nitrofurantoin) was observed
with age (Supplementary Material Table S2).
The high resistance rates observed in clinical isolates from UTIs
from the Bolivian Chaco were overall consistent with those reported
from other Latin American countries,1–4 and with data collected in
Bolivia by the Pan-American Health Organization (PAHO).5,32
One limitation of the present study, which might have
introduced a bias towards an overestimation of resistance rates,
is that in Bolivia microbiological diagnosis represents an extra cost
for the patient, and urine specimens for culture are rarely
requested by physicians for the diagnosis of uncomplicated UTIs.
In this scenario, it is likely that a number of the clinical isolates
from community-acquired UTIs originated from patients whose
initial empiric therapy had failed. The presence of such a selection
bias represents a general problem in studies addressing the
epidemiology of community-acquired uncomplicated UTIs,33,34
and is even more complicated in resource-limited countries for
issues related to weaknesses of healthcare systems and poverty.
3.3. Characterization of the enterobacterial isolates resistant to
expanded-spectrum cephalosporins
All 24 isolates that were resistant to expanded-spectrum
cephalosporins exhibited a multidrug resistance phenotype(deﬁned as resistance to at least three different classes of antibiotic
agents) (Table 3). In particular, susceptibility rates of expanded-
spectrum cephalosporin-resistant E. coli (n = 18) and K. pneumo-
niae (n = 6) were as follows, respectively: meropenem, 100% and
100%; fosfomycin, 83% and 83%; nitrofurantoin, 83% and 0%;
amikacin, 72% and 67%; trimethoprim–sulphamethoxazole, 33%
and 17%; gentamicin, 22% and 0%; tetracycline, 22% and 17%;
ciproﬂoxacin, 6% and 0%; nalidixic acid, 6% and 0% (Table 3).
All ESBL producers were found to harbour genes encoding
CTX-M-type enzymes. CTX-M-1 group variants were the most
prevalent (15 isolates, 68%), followed by CTX-M-9 group (seven
isolates, 32%) and CTX-M-2 group (one isolate, 5%), with one isolate
harbouring variants from two groups (Table 3). Sequencing of
blaCTX-M genes identiﬁed blaCTX-M-15 and blaCTX-M-65 as the most
prevalent variants (Table 3).
The 16 CTX-M-producing E. coli isolates belonged to each of the
four major phylogenetic groups (A, 38%; D, 31%; B2, 25%; B1, 6%),
with no speciﬁc association observed between CTX-M allelic
variants and phylogenetic groups (Table 3). Of note, all four CTX-
M-15-producing E. coli isolates belonging to phylogenetic group B2
were assigned to the pandemic clone ST131, with two isolates of
hospital origin belonging to the H30-Rx subclone.28–30,35
The two isolates producing AmpC-like enzymes were shown to
harbour blaCMY-2.
Altogether, the molecular epidemiology of CTX-M enzymes in
clinical isolates from the Bolivian Chaco appeared to be coherent
with their recent evolution in South America.1–3,14 The heteroge-
neity in terms of CTX-M allelic variants and population structure
(i.e., diverse E. coli phylogenetic groups) would exclude a major
role of clonal expansion in the dissemination of CTX-M ESBLs
among enterobacteria responsible for UTIs in the study setting, and
the investigation of plasmids encoding the most prevalent variant
(i.e., CTX-M-15) deserves further attention. Interestingly, the
urinary E. coli isolates analyzed in this study exhibited a
comparable prevalence of CTX-M producers (9% vs. 17%;
p = 0.07) and a similar distribution of CTX-M variants (CTX-M-
15: 56% vs. 38%, p = 0.4; CTX-M-65: 19% vs. 27%, p = 0.8) as those of
commensal E. coli collected in 2011 from healthy children living in
the same urban area,8 emphasizing the role of commensal
enterobacteria as a reservoir of clinically relevant resistance
determinants.
3.4. Detection of emerging aminoglycoside and fosfomycin resistance
genes
Acquired 16S rRNA methyltransferases (accounting for high-
level and broad-spectrum aminoglycoside resistance) and gluta-
thione S-transferases (accounting for fosfomycin resistance) have
been reported increasingly among enterobacterial isolates in
recent years, often in association with beta-lactamases, further
complicating the management of infections caused by multidrug-
resistant isolates.25,36–39 Although resistance to amikacin and
fosfomycin were uncommon in this setting, the isolates non-
susceptible to these drugs were screened for the presence of the
above resistance determinants.
All isolates exhibiting amikacin non-susceptibility (E. coli, n = 8;
K. pneumoniae, n = 2) were subjected to a multiplex PCR for the
detection of the 10 known 16S rRNA methyltransferase determi-
nants.25 Positive results for rmtB were obtained with the two
K. pneumoniae isolates. Both isolates also carried blaCTX-M-65,
suggesting a possible genetic linkage between the two resistance
determinants (not further investigated) (Table 3). The epidemiol-
ogy of plasmid-encoded 16S rRNA methyltransferases in South
America has been poorly investigated so far, with the few data
available pointing towards a dominance of RmtD-like enzymes and
the occasional occurrence of RmtB (in E. coli and Proteus mirabilis
Table 3
Phenotypic and molecular features of expanded-spectrum cephalosporin-resistant isolates from the Bolivian Chaco
Isolate Year Origina Other resistance traitsb CTX-M
group
CTX-M variantc Phylogenetic groupd Other relevant
resistance genes
E. coli VM-72 2011 H NAL, CIP, CN, TET 1 CTX-M-15 B2 (H30-Rx ST131) -
E. coli VM-292 2011 C NAL, CIP, CN, FOT, TET 9 CTX-M-65 D fosA3
E. coli VM-77 2012 C SXT, NAL, CIP, CN, TET 9 CTX-M-14 D -
E. coli VM-82 2012 C sxt, NAL, CIP, CN, TET 9 CTX-M-14 D -
E. coli VM-255 2012 C NAL, CIP, CN - - A blaCMY-2
E. coli VM-334 2012 H SXT, NAL, CIP, CN, NIT, TET 9 CTX-M-65 A -
E. coli VM-337 2012 C SXT, NAL, CIP, CN, NIT, TET 1 CTX-M-15 A -
E. coli VM-353 2013 H FOT, TET 1 CTX-M-55 A fosA3
E. coli VM-363 2013 C SXT, NAL, CIP, CN, AK, TET - - B1 blaCMY-2, aac(60)Ib
E. coli VM-364 2013 C SXT, NAL, CIP, CN, ak, TET 1 CTX-M-15 B2 (non-H30 ST131) aac(60)Ib-cr
E. coli VM-365 2013 C NAL, CIP, ak 1 CTX-M-15 A aac(60)Ib-cr
E. coli VM-366 2013 H SXT, NAL, CIP, CN, TET 9 CTX-M-65 A -
E. coli VM-379 2013 H SXT, NAL, CIP, CN, nit, TET 1 CTX-M-15 A -
E. coli VM-439 2013 H SXT, NAL, CIP 1 CTX-M-15 B1 -
E. coli VM-444 2013 C SXT, NAL, CIP, CN, AK, TET 1 CTX-M-15 B2 (non-H30 ST131) aac(60)Ib-cr
E. coli VM-474 2013 C SXT, NAL, CIP, CN 1 CTX-M-15 D -
E. coli VM-517 2013 U SXT, NAL, CIP, CN, FOT, TET 1 CTX-M-55 D fosA3
E. coli VM-498 2014 H NAL, CIP, ak, TET 1 CTX-M-15 B2 (H30-Rx ST131) aac(60)Ib-cr
K. pneumoniae
VM-249
2012 C SXT, NAL, CIP, CN, NIT, TET 1 CTX-M-15 ND -
K. pneumoniae
VM-354
2013 H SXT, NAL, CIP, CN, NIT, TET 1, 2 CTX-M-2, CTX-M-15 ND -
K. pneumoniae
VM-397
2013 C NAL, CIP, CN, AK, NIT, FOT, TET 9 CTX-M-65 ND fosA3, rmtB
K. pneumoniae
VM-419
2013 H SXT, NAL, CIP, CN, NIT, TET 1 CTX-M-15 ND -
K. pneumoniae
VM-466
2013 C SXT, NAL, CIP, CN, NIT 1 CTX-M-15 ND -
K. pneumoniae
VM-477
2013 H SXT, NAL, CIP, CN, AK, NIT, TET 9 CTX-M-65 ND rmtB, aac(60)Ib-cr
a H, hospital; C, community; U, unknown.
b SXT, trimethoprim–sulphamethoxazole; NAL, nalidixic acid; CIP, ciproﬂoxacin; CN, gentamicin; AK, amikacin; NIT, nitrofurantoin; FOT, fosfomycin; TET, tetracycline. For
the antibiotics, upper case indicates a resistance phenotype and lower case indicates an intermediate phenotype.
c All isolates (n = 24) were classiﬁed as potential extended-spectrum beta-lactamase (ESBL) producers (as per the Clinical and Laboratory Standards Institute (CLSI)) on the
basis of inhibition zone diameters of cefotaxime and/or ceftazidime smaller than the screening breakpoints (27 mm for cefotaxime and 22 mm for cefotaxime). The
phenotypic conﬁrmatory test for ESBL production (as per CLSI) was positive for 22 isolates using both cefotaxime and ceftazidime, with the exception of the two E. coli isolates
producing CTX-M-14 (E. coli VM-77 and E. coli VM-82) for which a 5 mm increase in inhibition zone diameter in the presence of clavulanic acid was observed only with
cefotaxime. The two CMY-2-producing E. coli isolates (E. coli VM-255 and E. coli VM-363) were negative by the modiﬁed CLSI conﬁrmatory test for ESBL detection in AmpC
producers, as recently proposed by Poulou et al.21
d ND, not determined.
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dissemination of RmtB among enterobacterial pathogens from this
epidemiological setting.
The amikacin non-susceptible phenotype of the remaining
isolates was found to be mostly the result of the presence of
aac(60)Ib and its variant aac(60)Ib-cr (detected in one and six
isolates, respectively; all but one resistant to expanded-spectrum
cephalosporins) (Table 3). These results conﬁrmed the dissemina-
tion of aac(60)Ib-cr (clinically relevant for its ability to reduce
susceptibility to both aminoglycosides and quinolones) in the study
setting,41 and its frequent association with ESBL determinants.
Among the seven isolates showing a fosfomycin non-suscepti-
ble phenotype (E. coli, n = 3; Morganella morganii, n = 3; K.
pneumoniae, n = 1), four were identiﬁed as producers of glutathi-
one S-transferases by a recently developed disk potentiation test
(i.e., all E. coli and K. pneumoniae isolates),22 and all of them were
found to harbour fosA3. Of note, all the fosA3-positive isolates were
also CTX-M producers (Table 3), conﬁrming the frequent associa-
tion of fosA3 with CTX-M determinants.42–44 The fosfomycin
resistance phenotype shown by the three M. morganii isolates was
not unexpected and conﬁrmed previous reports of a very low
susceptibility to this drug.45
3.5. Conclusions
In general, antimicrobial chemotherapy for uncomplicated
UTIs is selected empirically, based on guidelines that considerthe local epidemiology of antimicrobial resistance, which can be
very different in diverse geographical settings.3,33 This is the
ﬁrst study on the antimicrobial susceptibility of clinical isolates
from UTIs of patients in the Bolivian Chaco region, and one of the
ﬁrst from Bolivia. The present data indicate an overall high
resistance burden, with extremely high levels of resistance to
trimethoprim–sulphamethoxazole and ﬂuoroquinolones, and a
sizeable presence of ESBL determinants in Enterobacteriaceae,
suggesting that nitrofurantoin and fosfomycin might represent
the ﬁrst-line treatment options for uncomplicated UTIs in this
area.3,33
This is also the ﬁrst study to characterize antibiotic resistance
determinants in enterobacteria responsible for UTIs in Bolivia.
Among relevant ﬁndings, the emergence of FosA3 among ESBL-
producing isolates was noted and is of concern, since it could
impair the efﬁcacy of fosfomycin. The other alarming ﬁnding was
the emergence of RmtB, which compromises the activity of all
aminoglycosides, which in a similar setting could be important
options for complicated UTIs caused by multidrug-resistant
pathogens.
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